Wu, Y., Yang, S., Han, L., Shang, K., Zhang, B., Gai, X., . . . Zhang, H. (2023). β-catenin-IRP2-primed iron availability to mitochondrial metabolism is druggable for active β-catenin-mediated cancer. Journal of Translational Medicine, 21(1), 1. https://doi.org/10.1186/s12967-023-03914-0
Chicago-referens (17:e uppl.)Wu, Yuting, Shuhui Yang, Luyang Han, Kezhuo Shang, Baohui Zhang, Xiaochen Gai, Weiwei Deng, Fangming Liu, och Hongbing Zhang. "β-catenin-IRP2-primed Iron Availability to Mitochondrial Metabolism Is Druggable for Active β-catenin-mediated Cancer." Journal of Translational Medicine 21, no. 1 (2023): 1. https://doi.org/10.1186/s12967-023-03914-0.
MLA-referens (9:e uppl.)Wu, Yuting, et al. "β-catenin-IRP2-primed Iron Availability to Mitochondrial Metabolism Is Druggable for Active β-catenin-mediated Cancer." Journal of Translational Medicine, vol. 21, no. 1, 2023, p. 1, https://doi.org/10.1186/s12967-023-03914-0.
